BlackRock
SNDX icon

BlackRock’s Syndax Pharmaceuticals SNDX Stock Holding History

BlackRock’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197M Buy
9,020,006
+765,580
+9% +$15.9M ﹤0.01% 1805
2026
Q1 		$193M Buy
8,254,426
+15,424
+0.2% +$335K ﹤0.01% 1693
2025
Q4 		$173M Sell
8,239,002
-386,242
-4% -$6.74M ﹤0.01% 1776
2025
Q3 		$133M Sell
8,625,244
-1,831,663
-18% -$24M ﹤0.01% 1926
2025
Q2 		$97.9M Buy
10,456,907
+1,914,656
+22% +$21.1M ﹤0.01% 2061
2025
Q1 		$105M Sell
8,542,251
-491,698
-5% -$6.94M ﹤0.01% 1963
2024
Q4 		$119M Buy
9,033,949
+794,899
+10% +$13.6M ﹤0.01% 1973
2024
Q3 		$159M Buy
8,239,050
+332,285
+4% +$6.86M ﹤0.01% 1796
2024
Q2 		$162M Buy
7,906,765
+354,334
+5% +$7.42M ﹤0.01% 1743
2024
Q1 		$180M Buy
7,552,431
+536,883
+8% +$12M ﹤0.01% 1713
2023
Q4 		$152M Buy
7,015,548
+1,132,912
+19% +$17.4M ﹤0.01% 1834
2023
Q3 		$85.4M Buy
5,882,636
+891,652
+18% +$16.9M ﹤0.01% 2080
2023
Q2 		$104M Buy
4,990,984
+90,143
+2% +$1.88M ﹤0.01% 2022
2023
Q1 		$104M Buy
4,900,841
+548,809
+13% +$13.7M ﹤0.01% 1994
2022
Q4 		$111M Buy
4,352,032
+212,415
+5% +$4.95M ﹤0.01% 1921
2022
Q3 		$99.5M Buy
4,139,617
+343,708
+9% +$7.71M ﹤0.01% 1969
2022
Q2 		$73M Sell
3,795,909
-2,241
-0.1% -$37.3K ﹤0.01% 2234
2022
Q1 		$66M Buy
3,798,150
+108,256
+3% +$1.82M ﹤0.01% 2410
2021
Q4 		$80.8M Buy
3,689,894
+163,596
+5% +$3.02M ﹤0.01% 2352
2021
Q3 		$67.4M Buy
3,526,298
+6,404
+0.2% +$107K ﹤0.01% 2464
2021
Q2 		$60.4M Buy
3,519,894
+842,389
+31% +$15.4M ﹤0.01% 2575
2021
Q1 		$59.9M Buy
2,677,505
+357,099
+15% +$8.07M ﹤0.01% 2510
2020
Q4 		$51.6M Buy
2,320,406
+444,048
+24% +$9.21M ﹤0.01% 2454
2020
Q3 		$27.7M Sell
1,876,358
-265,711
-12% -$4.05M ﹤0.01% 2678
2020
Q2 		$31.7M Sell
2,142,069
-266,166
-11% -$4.05M ﹤0.01% 2539
2020
Q1 		$26.4M Buy
2,408,235
+693,754
+40% +$6.51M ﹤0.01% 2461
2019
Q4 		$15.1M Buy
1,714,481
+1,177
+0.1% +$8.64K ﹤0.01% 3038
2019
Q3 		$12.8M Buy
1,713,304
+31,797
+2% +$290K ﹤0.01% 3085
2019
Q2 		$15.7M Buy
1,681,507
+183,872
+12% +$1.34M ﹤0.01% 2984
2019
Q1 		$7.86M Sell
1,497,635
-77,296
-5% -$441K ﹤0.01% 3224
2018
Q4 		$7.01M Sell
1,574,931
-182,913
-10% -$1M ﹤0.01% 3262
2018
Q3 		$14.2M Buy
1,757,844
+87,028
+5% +$620K ﹤0.01% 3055
2018
Q2 		$11.7M Buy
1,670,816
+394,145
+31% +$3.87M ﹤0.01% 3157
2018
Q1 		$18.2M Buy
1,276,671
+126,941
+11% +$1.35M ﹤0.01% 2821
2017
Q4 		$10.1M Sell
1,149,730
-802,160
-41% -$7.94M ﹤0.01% 3147
2017
Q3 		$22.8M Buy
1,951,890
+62,781
+3% +$770K ﹤0.01% 2731
2017
Q2 		$26.4M Buy
1,889,109
+419,201
+29% +$4.79M ﹤0.01% 2637
2017
Q1 		$20.2M Buy
1,469,908
+1,425,057
+3,177% +$14.8M ﹤0.01% 2759
2016
Q4 		$322K Hold
44,851
– – ﹤0.01% 1878
2016
Q3 		$680K Hold
44,851
– – ﹤0.01% 1635
2016
Q2 		$442K Buy
44,851
+256
+0.6% +$3.51K ﹤0.01% 1719
2016
Q1 		$594K Buy
+44,595
New +$561K ﹤0.01% 1518

Other funds holding SNDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

BlackRock's SNDX Position: Q2 2026 in Review

BlackRock increased its Syndax Pharmaceuticals (SNDX) stake by 9.3% in Q2 2026, buying an estimated $15.9M and bringing the position to 9,020,006 shares worth $197M. The position accounts for ﹤0.01% of the portfolio, ranked #1805.

BlackRock first reported a position in SNDX in Q1 2016 and has held it in 42 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • BlackRock held 9,020,006 shares of Syndax Pharmaceuticals worth $197M as of Q2 2026.
  • BlackRock bought 765,580 Syndax Pharmaceuticals shares in Q2 2026, an estimated $15.9M.
  • Syndax Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1805 holding.
  • BlackRock first reported a position in Syndax Pharmaceuticals in Q1 2016 and has held it in 42 quarters since.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.